Abstract
The aim of the study was to evaluate the effect of intensive use of amikacin on the resistance levels to amikacin, gentamicin, tobramycin, netilmicin and dibekacin. The base-line resistance in the preamikacin phase (three months of amikacin use less than 1 %; 676 isolates) was 1.0 % for amikacin, 11.4 % for gentamicin, 8.0 % tobramycin, 6.2 % for netilmicin and 8.3 % for dibekacin. During the amikacin phase (36 months of average amikacin use of 89 %; 6048 isolates) there was no significant change in aminoglycoside resistance except for dibekacin (from 8.3 % to 10.9 %, 0.05>p>0.02). Isolated amikacin resistance was not observed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
O'Brien, T. F., andthe International Survey of Antibiotic Resistance Group Resistance to antibiotics at medical centres in different parts of the world. Journal of Antimicrobial Chemotherapy 1986, 18, Supplement C: 243–253.
Acar, J. F. Problems and changing patterns of resistance with gram-negative bacteria. Reviews of Infectious Diseases 1985, 7, Supplement 4: S545-S551.
Moore, R. D., Lietman, P. S., Smith, C. R. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. Journal of Infectious Diseases 1987, 155: 93–99.
Cross, A. S., Opal, S., Kopecko, D. J. Progressive increase in antibiotic resistance of gram-negative bacterial isolates: Walter Reed hospital, 1976 to 1980: specific analysis of gentamicin, tobramycin and amikacin resistance. Archives of Internal Medicine 1983, 143: 2075–2080.
Levine, J. F., Maslow, M. J., Leibowitz, R. E., Pollock, A. A., Hanna, B. A., Schaefler, S., Simberkoff, M. S., Rahal, J. J. Jr. Amikacin resistant gram-negative bacilli: correlation of occurrence with amikacin use. Journal of Infectious Diseases 1985, 151: 295–300.
Ma, M. Y., Goldstein, E. J. C., Friedman, M. H., Anderson, M. S., Mulligan, M. E. Resistance of gram-negative bacilli as related to hospital use of antimicrobial agents. Antimicrobial Agents and Chemotherapy 1983, 24: 347–352.
Mouton, R. P., Glerum, J. H., Van Loenen, A. C. Relationship between antibiotic consumption and frequency of antibiotic resistance of four pathogens: a seven-year survey. Journal of Antimicrobial Chemotherapy 1976, 2: 9–19.
Acar, J., Bergogne-Berezin, E., Chabert, Y., Cluzel, R., Courtieu, A., Courvalin, P., Dabernat, H., Drugeon, H., Duval, J., Fleurette, J., Morel, C., Philipon, A., Sirot, J., Soussy, C., Thabaut, A., Veron, M. Communiqué du comité de l'antibiogramme de la Société Française de Microbiologie. Pathologie et Biologie 1985, 33: 295–296.
Vanhoof, R., Hubrechts, J. M., Roebben, E., Clayes, M., Nulens, E., Nyssen, H. J., Van Haeverbeek, M., Van Gysel, J. P. A one-year survey on the epidemiology of aminoglycoside resistance in a general hospital: influence of amikacin. Acta Clinica Belgica 1986, 41: 248–254.
Martinez-Forde, J. M., Garcia-Caballero, J., Aguado-Matorras, A. Cefoxitin, amikacin andPseudomonas aeruginosa resistance. Lancet 1982, ii: 719–720.
Gerding, D. N., Larson, T. A. Aminoglycoside resistance in gram-negative bacilli during increased amikacin use. Comparison of experience in 14 United States hospitals with experience in Minneapolis Veterans Administration Medical Center. American Journal of Medicine 1985, 79, Supplement 1A: 1–7.
Gerding, D. N., Larson, T. A. Resistance surveillance programs and the incidence of gram-negative bacillary resistance to amikacin from 1967 to 1985. American Journal of Medicine 1986, 80, Supplement 6B: 22–28.
Price, K. E., Kresel, P. A., Farchione, S. B., Siskin, S. B., Karpow, S. A. Epidemiological studies of aminoglycoside resistance in the USA. Journal of Antimicrobial Chemotherapy 1981, 8, Supplement A: 89–105.
Larson, T. A., Garrett, C. R., Gerding, D. N. Frequency of aminoglycoside 6′-N-acetyltransferase amongSerratia species during increased use of amikacin in the hospital. Antimicrobial Agents and Chemotherapy 1986, 30: 176–178.
Kunin, C. M., Chambers, S. Responsibility of the infectious disease community for optimal use of antibiotics: views of the membership of the Infectious Diseases Society of America. Reviews of Infectious Disease 1985, 7: 547–559.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vanhoof, R., Hubrechts, J.M., Nyssen, H.J. et al. Three-year survey of amikacin use and aminoglycoside resistance in a general hospital in Belgium. Eur. J. Clin. Microbiol. Infect. Dis. 7, 183–185 (1988). https://doi.org/10.1007/BF01963076
Issue Date:
DOI: https://doi.org/10.1007/BF01963076